Financial reports
10-K
2023 FY
Annual report
29 Mar 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
ARS
2022 FY
Annual report to shareholders
15 May 23
10-Q
2023 Q1
Quarterly report
12 May 23
10-K
2022 FY
Annual report
20 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
15 Aug 22
10-Q
2022 Q1
Quarterly report
23 May 22
NT 10-Q
Notice of late quarterly filing
17 May 22
Current reports
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
22 Mar 24
8-K
First Wave BioPharma Announces Two Abstracts on Celiac Disease Research Accepted for Presentation at the 2024 Digestive Disease Week (DDW) Conference
18 Mar 24
8-K
Latiglutenase is a potentially first-in-class oral biotherapeutic for the treatment of celiac disease
14 Mar 24
8-K
First Wave BioPharma, Inc. to raise approximately $4.0 million of Gross Proceeds in Registered Direct Offering
5 Mar 24
8-K
First Wave BioPharma Chairman and CEO Issues Letter to Shareholders Highlighting Recent Accomplishments and Outlook for 2024
4 Jan 24
8-K
First Wave BioPharma Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $4.8 Million Gross Proceeds Priced
27 Dec 23
8-K
First Wave BioPharma Announces Streamlining of Clinical Pipeline with Non-Binding Term Sheet to Sell Niclosamide IBD Program
27 Dec 23
8-K
Other Events
18 Dec 23
8-K
First Wave BioPharma Announces 1-for-20 Reverse Stock Split and Results of the Special Meeting of Stockholders
14 Dec 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
31 Oct 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
4 Mar 24
424B3
Prospectus supplement
18 Jan 24
S-3
Shelf registration
8 Jan 24
RW
Registration withdrawal request
28 Dec 23
S-1/A
IPO registration (amended)
27 Dec 23
S-1/A
IPO registration (amended)
15 Dec 23
S-1
IPO registration
3 Nov 23
424B3
Prospectus supplement
2 Oct 23
S-3
Shelf registration
22 Sep 23
D
$1.47 mm in options, sold $1.47 mm, 1 investor
21 Sep 23
Proxies
DEFA14A
Additional proxy soliciting materials
18 Mar 24
DEFA14A
Additional proxy soliciting materials
14 Mar 24
DEF 14A
Definitive proxy
13 Nov 23
PRER14A
Preliminary revised proxy
31 Oct 23
PRE 14A
Preliminary proxy
12 Oct 23
DEF 14A
Definitive proxy
15 May 23
DEFA14A
Additional proxy soliciting materials
9 Jan 23
DEF 14A
Definitive proxy
16 Dec 22
PRE 14A
Preliminary proxy
7 Dec 22
DEF 14A
Definitive proxy
25 Jul 22
Other
EFFECT
Notice of effectiveness
18 Jan 24
CORRESP
Correspondence with SEC
16 Jan 24
UPLOAD
Letter from SEC
12 Jan 24
EFFECT
Notice of effectiveness
2 Oct 23
CORRESP
Correspondence with SEC
28 Sep 23
UPLOAD
Letter from SEC
26 Sep 23
EFFECT
Notice of effectiveness
18 Jul 23
CORRESP
Correspondence with SEC
14 Jul 23
CORRESP
Correspondence with SEC
14 Jul 23
CORRESP
Correspondence with SEC
14 Jul 23